| 1 |
35406579 | Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. | 2022 Apr 1 |
4 |
| 2 |
33767581 | Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model. | 2021 |
1 |
| 3 |
33984694 | PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice. | 2021 Aug |
1 |
| 4 |
34126369 | Corrigendum to "PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice" [Bioelectrochemistry 2021 (140) 107832]. | 2021 Oct |
1 |
| 5 |
34504648 | Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. | 2021 Aug 31 |
2 |
| 6 |
32134529 | Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling. | 2020 Apr |
3 |
| 7 |
32218813 | Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. | 2020 Apr |
1 |
| 8 |
32368391 | CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. | 2020 |
1 |
| 9 |
32444694 | Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. | 2020 Jun |
1 |
| 10 |
32546644 | Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays. | 2020 Sep 1 |
1 |
| 11 |
32604417 | The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. | 2020 Aug 1 |
1 |
| 12 |
30414739 | Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. | 2019 Jan |
1 |
| 13 |
30025822 | Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. | 2018 Sep |
3 |
| 14 |
27943283 | Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. | 2017 Mar |
1 |
| 15 |
28069724 | Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. | 2017 Jul 1 |
2 |
| 16 |
27323902 | A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. | 2016 Jun 21 |
1 |
| 17 |
27498558 | Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. | 2016 Aug 8 |
1 |
| 18 |
22759740 | Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. | 2012 Sep |
1 |